Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...

You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have such strong ...

HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...

Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...

Vertex Pharmaceuticals ( VRTX 3.06%) might be one of those special cases. Should you buy Vertex stock hand over fist before ...

Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.

The S&P 500’s health care sector (NYSEARCA:XLV), holding a weightage of 12.12% in the S&P 500 index, saw a fall of 10.2% in ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...